The U.S. Food and Drug Administration (FDA) is set to reclassify approximately 14 peptides previously deemed restricted, effective February 27, 2026. These short-chain amino acids, which enhance the skin's natural processes, play a vital role in collagen production, skin elasticity, and inflammation reduction. While the FDA's decision to move these peptides to Category 1 allows for legal access, it does not imply FDA approval for general use. The reclassification aims to mitigate the risks associated with unregulated peptide sales that have emerged in the grey market, where safety and quality control are often compromised. Notably, peptides such as GHK-Cu and BPC-157 are expected to be restored for use in skincare products. However, the FDA cautions that patients should seek treatments from licensed compounding pharmacies and consult healthcare professionals to ensure safety. In India, the reclassification could influence local dermatology practices and prompt regulatory bodies to enhance oversight on peptide usage, ensuring that patients receive safe and effective treatments.